Cas:84-23-1 benzo[e][1,2,3]benzoxadiazole-5-sulfonic acid manufacturer & supplier

Chemical Name:benzo[e][1,2,3]benzoxadiazole-5-sulfonic acid

CAS.NO:84-23-1

Synonyms:benzo[e][1,2,3]benzoxadiazole-5-sulfonic acid

Molecular Formula:C₁₀H₆N₂O₄S

Molecular Weight:250.23100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.671g/cm3

Index of Refraction:1.738

PSA:101.67000

Exact Mass:250.00500

LogP:2.70350

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like benzo[e][1,2,3]benzoxadiazole-5-sulfonic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,benzo[e][1,2,3]benzoxadiazole-5-sulfonic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,benzo[e][1,2,3]benzoxadiazole-5-sulfonic acid Use and application,benzo[e][1,2,3]benzoxadiazole-5-sulfonic acid technical grade,usp/ep/jp grade.

Related News: An active pharmaceutical ingredient (API) is a substance, or a mixture of ingredients, combined in the manufacture of a pharmaceutical or drug. benzo[e][1,2,3]benzoxadiazole-5-sulfonic acid manufacturer Today’s decisions represent progress in our continued efforts to make a difference in this pandemic on a global scale, Kathy Wengel, J&J’s chief global supply chain officer, said in the statement. benzo[e][1,2,3]benzoxadiazole-5-sulfonic acid supplier An active pharmaceutical ingredient (API) is a substance, or a mixture of ingredients, combined in the manufacture of a pharmaceutical or drug. benzo[e][1,2,3]benzoxadiazole-5-sulfonic acid vendor Eli Lilly and Roche have been riding high this week on the controversial approval of Biogen’s anti-amyloid Alzheimer’s disease drug Aduhelm (aducanumab), as its new low bar could help these Big Pharmas jump the finish line. benzo[e][1,2,3]benzoxadiazole-5-sulfonic acid factory The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward.